U.S. Markets open in 3 hrs 36 mins

Bristol-Myers Squibb and Starboard Value square off over Celgene deal

Ben Miller
Bristol-Myers Squibb and Starboard Value square off over Celgene deal

Activist investor says Bristol-Myers' Celgene deal "is ill-advised and could destroy substantial value for shareholders"; Bristol-Myers argues the deal "is a financially and strategically compelling transaction."